{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:35:16Z","timestamp":1780965316104,"version":"3.54.1"},"reference-count":103,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,25]],"date-time":"2023-11-25T00:00:00Z","timestamp":1700870400000},"content-version":"am","delay-in-days":542,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Presse M\u00e9dicale"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.lpm.2022.104144","type":"journal-article","created":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T03:11:44Z","timestamp":1667358704000},"page":"104144","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Pituitary adenoma & nuclear medicine: Recent outcomes and ongoing developments"],"prefix":"10.1016","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6449-3148","authenticated-orcid":false,"given":"Benjamin","family":"Chevalier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Jannin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Espiard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Merlen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amandine","family":"Beron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georges","family":"Lion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Christine","family":"Vantyghem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4986-9132","authenticated-orcid":false,"given":"Damien","family":"Huglo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Cortet-Rudelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clio","family":"Baillet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lpm.2022.104144_bib0001","first-page":"bnac010","article-title":"Clinical biology of the pituitary adenoma","author":"Melmed","year":"2022","journal-title":"Endocr Rev"},{"key":"10.1016\/j.lpm.2022.104144_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.beem.2019.05.002","article-title":"Modern imaging of pituitary adenomas","volume":"33","author":"Bashari","year":"2019","journal-title":"Best Practice Res Clin Endocrinol Metabol"},{"key":"10.1016\/j.lpm.2022.104144_bib0003","doi-asserted-by":"crossref","first-page":"263S","DOI":"10.2967\/jnumed.120.254532","article-title":"The future of nuclear medicine, molecular imaging, and theranostics","volume":"61","author":"Weber","year":"2020","journal-title":"J Nucl Med"},{"key":"10.1016\/j.lpm.2022.104144_bib0004","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41573-020-0073-9","article-title":"Radiopharmaceutical therapy in cancer: clinical advances and challenges","volume":"19","author":"Sgouros","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.lpm.2022.104144_bib0005","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/S0140-6736(14)61375-1","article-title":"Cushing's syndrome","volume":"386","author":"Lacroix","year":"2015","journal-title":"Lancet North Am Ed"},{"key":"10.1016\/j.lpm.2022.104144_bib0006","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S2213-8587(16)00086-3","article-title":"Complications of Cushing's syndrome: state of the art","volume":"4","author":"Pivonello","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.lpm.2022.104144_bib0007","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/S2213-8587(21)00235-7","article-title":"Consensus on diagnosis and management of Cushing's disease: a guideline update","volume":"9","author":"Fleseriu","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.lpm.2022.104144_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.ando.2022.02.001","article-title":"Consensus statement by the French Society of Endocrinology (SFE) and French Society of Pediatric Endocrinology & Diabetology (SFEDP) on diagnosis of Cushing's syndrome","author":"Tabarin","year":"2022","journal-title":"Annales d'Endocrinologie"},{"key":"10.1016\/j.lpm.2022.104144_bib0009","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.3390\/jcm11061558","article-title":"Clinical study and systematic review of pituitary microadenomas vs. Macroadenomas in cushing's disease: does size matter?","volume":"11","author":"Akirov","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.lpm.2022.104144_bib0010","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1210\/jc.2015-1818","article-title":"Treatment of Cushing's syndrome: an endocrine society clinical practice guideline","volume":"100","author":"Nieman","year":"2015","journal-title":"J Clin Endocrinol Metabol"},{"key":"10.1016\/j.lpm.2022.104144_bib0011","doi-asserted-by":"crossref","first-page":"3231","DOI":"10.1210\/JC.2015-1589","article-title":"Conventional and nuclear medicine imaging in ectopic Cushing's syndrome: A systematic review","volume":"100","author":"Isidori","year":"2015","journal-title":"J Clin EndocrinolMetabol"},{"key":"10.1016\/j.lpm.2022.104144_bib0012","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s11102-019-00972-w","article-title":"Diagnostic utility of Gallium-68-somatostatin receptor PET\/CT in ectopic ACTH-secreting tumors: a systematic literature review and single-center clinical experience","volume":"22","author":"Varlamov","year":"2019","journal-title":"Pituitary"},{"key":"10.1016\/j.lpm.2022.104144_bib0013","doi-asserted-by":"crossref","first-page":"4386","DOI":"10.1007\/s00259-021-05370-8","article-title":"Head-to-head comparison of 68Ga-DOTATATE PET\/CT and 18F-FDG PET\/CT in localizing tumors with ectopic adrenocorticotropic hormone secretion: a prospective study","volume":"48","author":"Liu","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.lpm.2022.104144_bib0014","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s11102-009-0180-4","article-title":"The diagnostic value of fused positron emission tomography\/computed tomography in the localization of adrenocorticotropin-secreting pituitary adenoma in Cushing's disease","volume":"12","author":"Alzahrani","year":"2009","journal-title":"Pituitary"},{"key":"10.1016\/j.lpm.2022.104144_bib0015","doi-asserted-by":"crossref","first-page":"750","DOI":"10.3171\/2009.7.JNS09285","article-title":"Usefulness of composite methionine\u2013positron emission tomography\/3.0-tesla magnetic resonance imaging to detect the localization and extent of early-stage Cushing adenoma: clinical article","volume":"112","author":"Ikeda","year":"2010","journal-title":"J Neurosurg"},{"key":"10.1016\/j.lpm.2022.104144_bib0016","doi-asserted-by":"crossref","first-page":"791","DOI":"10.3171\/2014.10.JNS14911","article-title":"High-resolution18F-fluorodeoxyglucose positron emission tomography and magnetic resonance imaging for pituitary adenoma detection in Cushing disease","volume":"122","author":"Chittiboina","year":"2015","journal-title":"JNS"},{"key":"10.1016\/j.lpm.2022.104144_bib0017","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s12020-019-01944-7","article-title":"CRH stimulation improves 18F-FDG-PET detection of pituitary adenomas in Cushing's disease","volume":"65","author":"Boyle","year":"2019","journal-title":"Endocrine"},{"key":"10.1016\/j.lpm.2022.104144_bib0018","doi-asserted-by":"crossref","first-page":"756","DOI":"10.2967\/jnumed.116.185587","article-title":"The impact of somatostatin receptor\u2013directed PET\/CT on the management of patients with neuroendocrine tumor: a systematic review and meta-analysis","volume":"58","author":"Barrio","year":"2017","journal-title":"J Nucl Med"},{"key":"10.1016\/j.lpm.2022.104144_bib0019","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1007\/s00259-012-2309-3","article-title":"68Ga-DOTA-TOC uptake in neuroendocrine tumour and healthy tissue: differentiation of physiological uptake and pathological processes in PET\/CT","volume":"40","author":"Kroiss","year":"2013","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.lpm.2022.104144_bib0020","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1111\/cen.14425","article-title":"Pre- and postoperative 68Ga-DOTATOC positron emission tomography for hormone-secreting pituitary neuroendocrine tumours","volume":"94","author":"Tj\u00f6rnstrand","year":"2021","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.lpm.2022.104144_bib0021","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s41824-021-00104-3","article-title":"The value of [68Ga]Ga-DOTA-TATE PET\/CT in diagnosis and management of suspected pituitary tumors","volume":"5","author":"Novruzov","year":"2021","journal-title":"Eur J Hybrid Imaging"},{"key":"10.1016\/j.lpm.2022.104144_bib0022","unstructured":"Pauwels E, Cleeren F, Bormans G, Deroose CM. Somatostatin receptor PET ligands - the next generation for clinical practice n.d.:21."},{"key":"10.1016\/j.lpm.2022.104144_bib0023","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1210\/clinem\/dgaa755","article-title":"Molecular imaging targeting corticotropin-releasing hormone receptor for corticotropinoma: a changing paradigm","volume":"106","author":"Walia","year":"2021","journal-title":"J Clin Endocrinol Metabol"},{"key":"10.1016\/j.lpm.2022.104144_bib0024","first-page":"1027","article-title":"Ga-68 mDesmo as a novel PET tracer to delineate corticotropinoma: a pilot study","volume":"62","author":"Shukla","year":"2021","journal-title":"J Nucl Med"},{"key":"10.1016\/j.lpm.2022.104144_bib0025","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s00259-012-2295-5","article-title":"Value of 11C-methionine PET in imaging brain tumours and metastases","volume":"40","author":"Glaudemans","year":"2013","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.lpm.2022.104144_bib0026","doi-asserted-by":"crossref","first-page":"M107","DOI":"10.1530\/EJE-15-0616","article-title":"A role for 11C-methionine PET imaging in ACTH-dependent Cushing's syndrome","volume":"173","author":"Koulouri","year":"2015","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.lpm.2022.104144_bib0027","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1007\/s11102-021-01160-5","article-title":"Selective resection of cushing microadenoma guided by preoperative hybrid 18-fluoroethyl-L-tyrosine and 11-C-methionine PET\/MRI","volume":"24","author":"Berkmann","year":"2021","journal-title":"Pituitary"},{"key":"10.1016\/j.lpm.2022.104144_bib0028","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/j.1365-2265.2009.03667.x","article-title":"Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK)","volume":"72","author":"Fernandez","year":"2010","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.lpm.2022.104144_bib0029","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1111\/j.1365-2265.2006.02493.x","article-title":"Influence of parasellar extension of macroprolactinomas defined by magnetic resonance imaging on their responsiveness to dopamine agonist therapy","volume":"64","author":"Delgrange","year":"2006","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.lpm.2022.104144_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.beem.2019.101290","article-title":"The epidemiology, diagnosis and treatment of prolactinomas: the old and the new","volume":"33","author":"Chanson","year":"2019","journal-title":"Best Pract Res Clin Endocrinol Metabol"},{"key":"10.1016\/j.lpm.2022.104144_bib0031","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1210\/jc.2010-1692","article-title":"Diagnosis and treatment of hyperprolactinemia: an endocrine society clinical practice guideline","volume":"96","author":"Melmed","year":"2011","journal-title":"JClin Endocrinol Metabol"},{"key":"10.1016\/j.lpm.2022.104144_bib0032","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s41016-022-00277-1","article-title":"Are dopamine agonists still the first-choice treatment for prolactinoma in the era of endoscopy? A systematic review and meta-analysis","volume":"8","author":"Cai","year":"2022","journal-title":"Chin Neurosurg Jl"},{"key":"10.1016\/j.lpm.2022.104144_bib102","doi-asserted-by":"crossref","unstructured":"Andereggen L, Frey J, Andres RH, El-Koussy M, Beck J, Seiler RW, Christ E. 10-year follow-up study comparing primary medical vs. surgical therapy in women with prolactinomas. Endocrine. 2017 Jan;55(1):223-230. doi: 10.1007\/s12020-016-1115-2. Epub 2016 Sep 29","DOI":"10.1007\/s12020-016-1115-2"},{"key":"10.1016\/j.lpm.2022.104144_bib0033","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1097\/RLU.0b013e3181d19098","article-title":"Occult prolactinoma diagnosed by FDG PET\/CT","volume":"35","author":"Gemmel","year":"2010","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.lpm.2022.104144_bib0034","doi-asserted-by":"crossref","first-page":"e130","DOI":"10.1097\/RLU.0000000000001085","article-title":"Utility of 11C-methionine and 18F-FDG PET\/CT in patients with functioning pituitary adenomas","volume":"41","author":"Feng","year":"2016","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.lpm.2022.104144_bib0035","doi-asserted-by":"crossref","unstructured":"Jaquet P, Ouafik L, Saveanu A, Gunz G, Fina F, Dufour H, et al. Quantitative and functional expression of somatostatin receptor subtypes in human prolactinomas 1999;84:9.","DOI":"10.1210\/jc.84.9.3268"},{"key":"10.1016\/j.lpm.2022.104144_bib0036","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1530\/eje.0.1360369","article-title":"Results of somatostatin receptor scintigraphy do not predict pituitary tumor volume- and hormone-response to ocreotide therapy and do not correlate with tumor histology","volume":"136","author":"Pl\u00f6ckinger","year":"1997","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.lpm.2022.104144_bib0037","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1097\/00006231-199812000-00004","article-title":"Pituitary adenomas: the role of 111In-DTPA-octreotide SPET in the detection of minimal post-surgical residues","volume":"19","author":"Lauriero","year":"1998","journal-title":"Nucl Med Commun"},{"key":"10.1016\/j.lpm.2022.104144_bib0038","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1046\/j.1365-2265.1996.8650876.x","article-title":"In vivo imaging of pituitary tumours using a radiolabelled dopamine D2 receptor radioligand","volume":"45","author":"de Herder","year":"1996","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.lpm.2022.104144_bib0039","first-page":"1931","article-title":"Dopamine D2 receptor imaging in pituitary adenomas using iodine-123-epidepride and SPECT","volume":"37","author":"Pirker","year":"1996","journal-title":"J Nucl Med"},{"key":"10.1016\/j.lpm.2022.104144_bib0040","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1046\/j.1365-2265.2000.00951.x","article-title":"Hormone levels and tumour size response to quinagolide and cabergoline in patients with prolactin-secreting and clinically non-functioning pituitary adenomas: predictive value of pituitary scintigraphy with 123I-methoxybenzamide","volume":"52","author":"Colao","year":"2000","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.lpm.2022.104144_bib0041","first-page":"406","article-title":"In vivo measurement of dopamine receptors in pituitary adenomas using positron emission tomography","volume":"369","author":"Muhr","year":"1986","journal-title":"Acta Radiol Suppl"},{"key":"10.1016\/j.lpm.2022.104144_bib0042","doi-asserted-by":"crossref","first-page":"286","DOI":"10.4103\/wjnm.WJNM_83_20","article-title":"18 F-fallypride and 11 C-methionine positron emission tomography\/computed tomography for the study of prolactinomas and nonfunctioning pituitary adenomas: a case series","volume":"20","author":"Damian","year":"2021","journal-title":"World J Nucl Med"},{"key":"10.1016\/j.lpm.2022.104144_bib0043","doi-asserted-by":"crossref","first-page":"e383","DOI":"10.1097\/RLU.0000000000001721","article-title":"18F-FDOPA PET imaging in prolactinoma","volume":"42","author":"Ginet","year":"2017","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.lpm.2022.104144_bib0044","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1210\/js.2018-00193","article-title":"Visualization of macroprolactinoma by 18F-fluorocholine PET\/CT in a patient with multiple endocrine neoplasia type 1","volume":"2","author":"Paepegaey","year":"2018","journal-title":"J Endocrine Soc"},{"key":"10.1016\/j.lpm.2022.104144_bib0045","doi-asserted-by":"crossref","DOI":"10.1007\/s11102-022-01229-9","article-title":"11C-methionine PET aids localization of microprolactinomas in patients with intolerance or resistance to dopamine agonist therapy","author":"Bashari","year":"2022","journal-title":"Pituitary"},{"key":"10.1016\/j.lpm.2022.104144_bib0046","doi-asserted-by":"crossref","DOI":"10.1007\/s11102-022-01230-2","article-title":"Implementation of functional imaging using 11C-methionine PET-CT co-registered with MRI for advanced surgical planning and decision making in prolactinoma surgery","author":"Bakker","year":"2022","journal-title":"Pituitary"},{"key":"10.1016\/j.lpm.2022.104144_bib0047","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s41572-019-0071-6","article-title":"Acromegaly","volume":"5","author":"Colao","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.lpm.2022.104144_bib0048","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/s41574-018-0058-5","article-title":"A consensus statement on acromegaly therapeutic outcomes","volume":"14","author":"Melmed","year":"2018","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.lpm.2022.104144_bib0049","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11102-020-01091-7","article-title":"A Pituitary Society update to acromegaly management guidelines","volume":"24","author":"Fleseriu","year":"2021","journal-title":"Pituitary"},{"issue":"11","key":"10.1016\/j.lpm.2022.104144_bib103","first-page":"871","article-title":"T2-weighted MRI signal predicts hormone and tumor responses to somatostatin analogs in acromegaly.Endocr Relat","volume":"23","author":"Potorac","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.lpm.2022.104144_bib0050","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1159\/000094315","article-title":"Acromegaly: molecular expression of somatostatin receptor subtypes and treatment outcome","volume":"35","author":"Bronstein","year":"2006","journal-title":"Front Horm Res"},{"key":"10.1016\/j.lpm.2022.104144_bib0051","first-page":"2356","article-title":"Prediction of efficacy of octreotide therapy in patients with acromegaly","volume":"81","author":"Colao","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.lpm.2022.104144_bib0052","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1007\/s40618-021-01523-6","article-title":"Evaluation of 68Ga-DOTATATE uptake at the pituitary region and the biochemical response to somatostatin analogs in acromegaly","volume":"44","author":"Daniel","year":"2021","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.lpm.2022.104144_bib0053","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1097\/RLU.0000000000000535","article-title":"CyberKnife radiosurgery planning of a secreting pituitary adenoma performed with 68Ga DOTATATE PET and MRI","volume":"39","author":"d'Amico","year":"2014","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.lpm.2022.104144_bib0054","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.wneu.2017.04.032","article-title":"Preoperative evaluation of sellar and parasellar macrolesions by [18 F]fluorodeoxyglucose positron emission tomography","volume":"103","author":"Tosaka","year":"2017","journal-title":"World Neurosurg"},{"key":"10.1016\/j.lpm.2022.104144_bib0055","doi-asserted-by":"crossref","first-page":"E8","DOI":"10.3171\/2020.3.FOCUS2052","article-title":"PET-guided repeat transsphenoidal surgery for previously deemed unresectable lateral disease in acromegaly","volume":"48","author":"Bashari","year":"2020","journal-title":"Neurosurg Focus"},{"key":"10.1016\/j.lpm.2022.104144_bib0056","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1007\/s00259-021-05458-1","article-title":"Positive [18F]fluoroethyltyrosine PET\/MRI in suspected recurrence of growth hormone\u2013producing pituitary adenoma in a paediatric patient","volume":"49","author":"Veldhuijzen van Zanten","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.lpm.2022.104144_bib0057","doi-asserted-by":"crossref","first-page":"R375","DOI":"10.1530\/ERC-20-0136","article-title":"The natural history and treatment of non-functioning pituitary adenomas (non-functioning PitNETs)","volume":"27","author":"Yavropoulou","year":"2020","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.lpm.2022.104144_bib0058","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s11102-018-0869-3","article-title":"Epidemiology, clinical presentation and diagnosis of non-functioning pituitary adenomas","volume":"21","author":"Ntali","year":"2018","journal-title":"Pituitary"},{"key":"10.1016\/j.lpm.2022.104144_bib0059","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3389\/fendo.2019.00007","article-title":"Molecular network basis of invasive pituitary adenoma: a review","volume":"10","author":"Yang","year":"2019","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.lpm.2022.104144_bib0060","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.ando.2015.04.002","article-title":"Management of clinically non-functioning pituitary adenoma","volume":"76","author":"Chanson","year":"2015","journal-title":"Annales d'Endocrinologie"},{"key":"10.1016\/j.lpm.2022.104144_bib0061","doi-asserted-by":"crossref","first-page":"81","DOI":"10.3904\/kjim.2013.28.1.81","article-title":"Analysis of 18 F-fluorodeoxyglucose positron emission tomography findings in patients with pituitary lesions","volume":"28","author":"Seok","year":"2013","journal-title":"Korean J Intern Med"},{"key":"10.1016\/j.lpm.2022.104144_bib0062","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1530\/ERC-14-0472","article-title":"SSTR3 is a putative target for the medical treatment of gonadotroph adenomas of the pituitary","volume":"22","author":"Lee","year":"2015","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.lpm.2022.104144_bib0063","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1210\/jc.2011-3163","article-title":"Expression of Ki-67, PTTG1, FGFR4, and SSTR 2, 3, and 5 in nonfunctioning pituitary adenomas: a high throughput TMA, immunohistochemical study","volume":"97","author":"Ram\u00edrez","year":"2012","journal-title":"J Clin Endocrinol Metabol"},{"key":"10.1016\/j.lpm.2022.104144_bib0064","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s41824-020-0073-3","article-title":"68Ga-DOTATATE PET imaging in clinically non-functioning pituitary macroadenomas","volume":"4","author":"Boertien","year":"2020","journal-title":"Eur J Hybrid Imaging"},{"key":"10.1016\/j.lpm.2022.104144_bib0065","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/cen.14144","article-title":"Lower 68Ga-DOTATOC uptake in nonfunctioning pituitary neuroendocrine tumours compared to normal pituitary gland\u2014a proof-of-concept study","volume":"92","author":"Tj\u00f6rnstrand","year":"2020","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.lpm.2022.104144_bib0066","doi-asserted-by":"crossref","first-page":"e460","DOI":"10.1097\/RLU.0000000000001328","article-title":"Pituitary non-functioning adenoma disclosed at 18F-Choline PET\/CT to investigate a prostate cancer relapse","volume":"41","author":"Maffione","year":"2016","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.lpm.2022.104144_bib0067","doi-asserted-by":"crossref","first-page":"R183","DOI":"10.1530\/EJE-16-1029","article-title":"DIAGNOSIS OF ENDOCRINE DISEASE: diagnostic approach to TSH-producing pituitary adenoma","volume":"177","author":"Tj\u00f6rnstrand","year":"2017","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.lpm.2022.104144_bib0068","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1530\/eje.0.1480433","article-title":"The changing spectrum of TSH-secreting pituitary adenomas: diagnosis and management in 43 patients","volume":"148","author":"Socin","year":"2003","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.lpm.2022.104144_bib0069","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1159\/000351007","article-title":"2013 European Thyroid Association Guidelines for the diagnosis and treatment of thyrotropin-secreting pituitary tumors","volume":"2","author":"Beck-Peccoz","year":"2013","journal-title":"Eur Thyroid J"},{"key":"10.1016\/j.lpm.2022.104144_bib0070","first-page":"4","article-title":"Indium-111 pentetreotide single-photon emission tomography in patients with TSH-secreting pituitary adenomas: Correlation with the effect of a single administration of octreotide on serum","volume":"24","author":"Losa","year":"1997","journal-title":"TSH Levels"},{"key":"10.1016\/j.lpm.2022.104144_bib0071","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1097\/RLU.0000000000001628","article-title":"Pituitary adenoma recurrence suspected on central hyperthyroidism despite empty sella and confirmed by 68Ga-DOTA-TOC PET\/CT","volume":"42","author":"Gauth\u00e9","year":"2017","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.lpm.2022.104144_bib0072","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s13550-022-00899-7","article-title":"Localization of TSH-secreting pituitary adenoma using 11C-methionine image subtraction","volume":"12","author":"Gillett","year":"2022","journal-title":"EJNMMI Res"},{"key":"10.1016\/j.lpm.2022.104144_bib0073","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/S2213-8587(16)30311-4","article-title":"Localisation of an occult thyrotropinoma with 11 C-methionine PET-CT before and after somatostatin analogue therapy","volume":"4","author":"Koulouri","year":"2016","journal-title":"Lancet Diabet Endocrinol"},{"key":"10.1016\/j.lpm.2022.104144_bib0074","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/s41574-021-00550-w","article-title":"Aggressive pituitary tumours and pituitary carcinomas","volume":"17","author":"Raverot","year":"2021","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.lpm.2022.104144_bib0075","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1210\/jc.2011-1166","article-title":"Pituitary carcinoma with malignant growth from first presentation and fulminant clinical course\u2013case report and review of the literature","volume":"96","author":"Dudziak","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.lpm.2022.104144_bib0076","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1530\/EJE-16-0979","article-title":"Temozolomide treatment can improve overall survival in aggressive pituitary tumors and pituitary carcinomas","volume":"176","author":"Lasolle","year":"2017","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.lpm.2022.104144_bib0077","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.3390\/jcm8081107","article-title":"Emerging and novel treatments for pituitary tumors","volume":"8","author":"Ilie","year":"2019","journal-title":"JCM"},{"key":"10.1016\/j.lpm.2022.104144_bib0078","doi-asserted-by":"crossref","first-page":"88","DOI":"10.3390\/jpm10030088","article-title":"Immunotherapy in corticotroph and lactotroph aggressive tumors and carcinomas: two case reports and a review of the literature","volume":"10","author":"Duhamel","year":"2020","journal-title":"J Personalized Med"},{"key":"10.1016\/j.lpm.2022.104144_bib0079","doi-asserted-by":"crossref","DOI":"10.1530\/EJE-22-0647","article-title":"Real-life efficacy and predictors of response to immunotherapy in pituitary tumors: a cohort study","author":"Ilie","year":"2022","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.lpm.2022.104144_bib0080","doi-asserted-by":"crossref","DOI":"10.1038\/s41571-022-00652-y","article-title":"Radiotheranostics in oncology: current challenges and emerging opportunities","author":"Bodei","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.lpm.2022.104144_bib0081","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1210\/jc.2018-01991","article-title":"Symptomatic and radiological response to 177Lu-DOTATATE for the treatment of functioning pancreatic neuroendocrine tumors","volume":"104","author":"Zandee","year":"2019","journal-title":"J Clin Endocrinol Metabol"},{"key":"10.1016\/j.lpm.2022.104144_bib0082","doi-asserted-by":"crossref","first-page":"e3665","DOI":"10.1210\/clinem\/dgab289","article-title":"Peptide receptor radionuclide therapy with 177Lu-DOTATATE for symptomatic control of refractory carcinoid syndrome","volume":"106","author":"Zandee","year":"2021","journal-title":"J Clin Endocrinol Metabol"},{"key":"10.1016\/j.lpm.2022.104144_bib0083","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 trial of 177 Lu-Dotatate for midgut neuroendocrine tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2022.104144_bib0084","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1016\/S1470-2045(21)00572-6","article-title":"177Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial","volume":"22","author":"Strosberg","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.lpm.2022.104144_bib0085","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.2967\/jnumed.114.144386","article-title":"High prognostic value of 18F-FDG PET for metastatic gastroenteropancreatic neuroendocrine tumors: a long-term evaluation","volume":"55","author":"Bahri","year":"2014","journal-title":"J Nucl Med"},{"key":"10.1016\/j.lpm.2022.104144_bib0086","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-17-0796","article-title":"European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas","volume":"178","author":"Raverot","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.lpm.2022.104144_bib0087","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.1007\/s00701-021-04953-6","article-title":"Aggressive pituitary neuroendocrine tumors: current practices, controversies, and perspectives, on behalf of the EANS skull base section","volume":"163","author":"Ng","year":"2021","journal-title":"Acta Neurochir"},{"key":"10.1016\/j.lpm.2022.104144_bib0088","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/j.jacr.2018.03.037","article-title":"Management of incidental pituitary findings on CT, MRI, and 18 F-fluorodeoxyglucose PET: a white paper of the ACR incidental findings committee","volume":"15","author":"Hoang","year":"2018","journal-title":"J Am Coll Radiol"},{"key":"10.1016\/j.lpm.2022.104144_bib0089","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ejim.2019.08.008","article-title":"The pituitary in nuclear medicine imaging","volume":"68","author":"Iglesias","year":"2019","journal-title":"Eur J Intern Mede"},{"key":"10.1016\/j.lpm.2022.104144_bib0090","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s11102-011-0373-5","article-title":"First demonstration of the effectiveness of peptide receptor radionuclide therapy (PRRT) with 111In-DTPA-octreotide in a giant PRL-secreting pituitary adenoma resistant to conventional treatment","volume":"15","author":"Baldari","year":"2012","journal-title":"Pituitary"},{"key":"10.1016\/j.lpm.2022.104144_bib0091","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1007\/s11102-013-0540-y","article-title":"Peptide receptor radionuclide therapy for aggressive atypical pituitary adenoma\/carcinoma: variable clinical response in preliminary evaluation","volume":"17","author":"Maclean","year":"2014","journal-title":"Pituitary"},{"key":"10.1016\/j.lpm.2022.104144_bib0092","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s11102-013-0494-0","article-title":"Peptide receptor radionuclide therapy in a patient with disabling non-functioning pituitary adenoma","volume":"17","author":"Komor","year":"2014","journal-title":"Pituitary"},{"key":"10.1016\/j.lpm.2022.104144_bib0093","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/RLU.0000000000000589","article-title":"The use of 68Ga DOTATATE PET\/CT for diagnostic assessment and monitoring of 177Lu DOTATATE therapy in pituitary carcinoma","volume":"40","author":"Novruzov","year":"2015","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.lpm.2022.104144_bib0094","doi-asserted-by":"crossref","first-page":"346","DOI":"10.3171\/2015.6.JNS15363","article-title":"Growth hormone\u2013secreting macroadenoma of the pituitary gland successfully treated with the radiolabeled somatostatin analog 90Y-DOTATATE: case report","volume":"125","author":"Walig\u00f3rska-Stachura","year":"2016","journal-title":"J Neurosurg"},{"key":"10.1016\/j.lpm.2022.104144_bib0095","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1530\/EC-19-0065","article-title":"Peptide receptor radionuclide therapy for aggressive pituitary tumors: a monocentric experience","volume":"8","author":"Giuffrida","year":"2019","journal-title":"Endocrine Connections"},{"key":"10.1016\/j.lpm.2022.104144_bib0096","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1007\/s00259-019-04578-z","article-title":"An aggressive functioning pituitary adenoma treated with peptide receptor radionuclide therapy","volume":"47","author":"Assadi","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.lpm.2022.104144_bib0097","doi-asserted-by":"crossref","DOI":"10.1530\/EJE-22-0440","article-title":"Aggressive pituitary tumours and carcinomas, characteristics and management of 171 patients","author":"Burman","year":"2022","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.lpm.2022.104144_bib0098","doi-asserted-by":"crossref","first-page":"bvab133","DOI":"10.1210\/jendso\/bvab133","article-title":"Synergism of Checkpoint Inhibitors and Peptide Receptor Radionuclide Therapy in the Treatment of Pituitary Carcinoma","volume":"5","author":"Lin","year":"2021","journal-title":"J Endocrine Soc"},{"key":"10.1016\/j.lpm.2022.104144_bib0099","first-page":"150","article-title":"18F-FDG PET\/MRI versus 18F-FDG PET\/CT for the diagnosis of pituitary adenoma","volume":"59","author":"Wang","year":"2018","journal-title":"J Nucl Med"},{"key":"10.1016\/j.lpm.2022.104144_bib0100","doi-asserted-by":"crossref","first-page":"523","DOI":"10.2967\/jnumed.117.191916","article-title":"PET\/MRI in the diagnosis of hormone-producing pituitary microadenoma: a prospective pilot study","volume":"59","author":"Wang","year":"2018","journal-title":"J Nucl Med"},{"key":"10.1016\/j.lpm.2022.104144_bib0101","series-title":"Endotext","article-title":"Development and microscopic anatomy of the pituitary gland","author":"Larkin","year":"2000"}],"container-title":["La Presse M\u00e9dicale"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498222000379?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498222000379?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:10:10Z","timestamp":1760105410000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0755498222000379"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":103,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["S0755498222000379"],"URL":"https:\/\/doi.org\/10.1016\/j.lpm.2022.104144","relation":{},"ISSN":["0755-4982"],"issn-type":[{"value":"0755-4982","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pituitary adenoma & nuclear medicine: Recent outcomes and ongoing developments","name":"articletitle","label":"Article Title"},{"value":"La Presse M\u00e9dicale","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lpm.2022.104144","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104144"}}